Investigational New Drugs

, Volume 23, Issue 4, pp 369–375 | Cite as

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

  • Nicolas Tsavaris
  • Christos Kosmas
  • Helias Skopelitis
  • Panagiotis Gouveris
  • Petros Kopteridis
  • Dioynissis Loukeris
  • Frantzeska Sigala
  • Alexandra Zorbala-Sypsa
  • Evangelos Felekouras
  • Efstathios Papalambros


Study objectives: The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas. Patients and methods: Patients with advanced pancreatic cancer previously treated with Gemcitabine were included in the study. All patients had histologically or cytologically confirmed adenocarcinoma of the pancreas that was unresectable, locally advanced or metastatic. Treatment consisted of Oxaliplatin 50 mg/m2 (2-hour iv infusion), followed by Leucovorin 50 mg/m2 (i.v. bolus) and 500 mg/m2 5-FU (1-hour iv infusion), administered weekly, until unacceptable toxicity or disease progression. Objective tumour response and toxicity were evaluated according to World Health Organisation (WHO) criteria. Results: A total of 30 patients, 20 men and 10 women, median age 63 years (range 52–71 years) and Karnofsky Performance Status (PS) of ≥50 entered the study. The majority of patients (96%) had locally advanced disease. A total of 380 doses of chemotherapy were delivered, a median of 12 doses per patient. Partial responses were observed in 7 patients (PR 23.3%), stable disease in 9 (SD 30.0%), while 14 patients progressed (PD 46.7%). Improved PS was observed in 18 (42.8%) patients. Patients that had responded to first-line Gemcitabine treatment were found more likely to respond or stabilize their disease with second-line treatment. The median duration of response was 22 weeks, and median overall survival was 25 weeks, Grade 3/4 toxicity expressed per chemotherapy dose included leukopenia 16%, anemia 3.2%, thrombocytopenia 3.2%, diarrhea 14.2%, fatigue 16.1% and neurotoxicity 4.2%. Eight patients (27%) suffered a febrile neutropenic event managed successfully with oral antibiotic home therapy, while 17 patients required G-CSF support. There were no treatment related deaths. Conclusions: The combination of Oxaliplatin, Leucovorin and 5-FU was tolerated with manageable toxicity, offering encouraging activity as second-line treatment of patients with advanced or metastatic pancreatic adenocarcinoma, previously treated with Gemcitabine. Additional studies are warranted with this regimen in Gemcitabine relapsed pancreatic cancer patients.


pancreatic cancer chemotehrapy oxaliplatin 5-FU leucovorin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fernandez E, La Vecchia C, Porta M, Negri E, Lucchini F, Levi F: Trends in pancreatic cancer mortality in Europe, 1955–1989. Int J Cancer 57: 786, 1994PubMedGoogle Scholar
  2. 2.
    Landis SH, Murray T, Bolden S,Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 48: 6–29, 1998PubMedGoogle Scholar
  3. 3.
    Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds), Cancer: Principles and practice of oncology, 5th edition. Philadelphia, PA: Lippincott 1997, pp. 1054–1087Google Scholar
  4. 4.
    Williamson RCN: Pancreatic cancer: the greatest oncological challenge. Br Med J 296: 445, 1991Google Scholar
  5. 5.
    Permert J, Hafstrom L, Nygren P, Glimelius B: A systematic overview of chemotherapy effects in pancreatic cancer. Acta Oncol 40: 361–370, 2001PubMedGoogle Scholar
  6. 6.
    Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, Bosset JF, Merouche Y, Raoul JL, Ychou M, Adenis A, Berthault-Cvitkovic F, Luboinski M: A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13: 1185–1191, 2002CrossRefPubMedGoogle Scholar
  7. 7.
    Lutz MP, Koniger M, Muche R, Ellenrieder V, Steinkamp M, Adler G, Gress TM: A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z Gastroenterol 37: 993–997, 1999PubMedGoogle Scholar
  8. 8.
    Raderer M, Kornek GV, Hejna MH, Weinlaender G, Vorbeck F, Fiebiger WC, Scheithauer W: Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: A phase II study. Ann Oncol 8: 797–799, 1997CrossRefPubMedGoogle Scholar
  9. 9.
    Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593–600, 1996PubMedGoogle Scholar
  10. 10.
    Von Hoff DD, Goodwin AL, Garcia L: Advances in the treatment of patients with pancreatic cancer: Improvement in symptoms and survivial time. The San Antonio Drug Development Team. Br J Cancer, 78(suppl 3): 9–13, pp. 1998.PubMedGoogle Scholar
  11. 11.
    Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur J Cancer 33(suppl 1): S18–S22, 1997PubMedGoogle Scholar
  12. 12.
    Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403–2413, 1997PubMedGoogle Scholar
  13. 13.
    Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347–353, 1996PubMedGoogle Scholar
  14. 14.
    Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Grupo Oncologia dell’Italia Meridionale. Cancer 94: 902–910, 2002CrossRefPubMedGoogle Scholar
  15. 15.
    Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92: 569–577, 2001CrossRefPubMedGoogle Scholar
  16. 16.
    Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270–3275, 2002CrossRefPubMedGoogle Scholar
  17. 17.
    Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W: Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88: 1180–1184, 2003CrossRefPubMedGoogle Scholar
  18. 18.
    Boxberger F, Happich K, Schirner I, Brueckl WM, Hohenberger W, Hahn EG, Wein A: Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma. Z Gastroenterol 40: 881–884, 2002CrossRefPubMedGoogle Scholar
  19. 19.
    Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW: Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6: 488–495, 2001CrossRefPubMedGoogle Scholar
  20. 20.
    Oettle H, Arnold D, Esser M, Huhn D, Riess H: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11: 635–638, 2000CrossRefPubMedGoogle Scholar
  21. 21.
    Hoff PM, Fuchs CS: The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas. Semin Oncol 30(4 Suppl 15): 54–61, 2003PubMedGoogle Scholar
  22. 22.
    Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA: Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II study. Ann Oncol 14: 580–585, 2003PubMedGoogle Scholar
  23. 23.
    Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore DF Jr, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA, Sargent DJ: Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: A North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 13: 553–557, 2002CrossRefPubMedGoogle Scholar
  24. 24.
    Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 20: 1512–1518, 2002PubMedGoogle Scholar
  25. 25.
    von Hoff DD, Beares D: New drugs for patients with pancreatic cancer. Curr Opin Oncol 14: 621–627, 2002CrossRefPubMedGoogle Scholar
  26. 26.
    Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O’Brien M, Tebbutt N, Harrington A, Hill M: Multicenter randomized phase III trial of protracted venous infusion of 5-flourouracil with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20: 3130–3136, 2002CrossRefPubMedGoogle Scholar
  27. 27.
    Taieb J, Lecomte T, Ezenfis J, Artru P, Mitry E, Boige V, Clavero-Fabri MC, Vaillant JN, Rougier P, Ducreux M: 5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer. Gastroenterol Clin Biol 26: 605–609, 2002PubMedGoogle Scholar
  28. 28.
    Petty RD, Nicolson MC, Skaria S, Sinclair TS, Samuel LM, Koruth M: Aberdeen Pancreatic Cancer Focus Group. A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: Efficacy and low toxicity. Ann Oncol 14: 1100–1105, 2003CrossRefPubMedGoogle Scholar
  29. 29.
    Adsay NV, El-Rayes BF, Philip PA: Pancreatic cancer: The evolving role of systemic therapy. Expert Opin Pharmacother 2: 1939–1947, 2001PubMedGoogle Scholar
  30. 30.
    Magistrelli P, Antinori A, Crucitti A, La Greca A, Masetti R, Coppola R, Nuzzo G, Picciocchi A: Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 74: 36–40, 2000CrossRefPubMedGoogle Scholar
  31. 31.
    Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T: Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91: 490–495, 2001CrossRefPubMedGoogle Scholar
  32. 32.
    Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG: Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89: 1413–1417, 2003CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Nicolas Tsavaris
    • 1
  • Christos Kosmas
    • 2
  • Helias Skopelitis
    • 1
  • Panagiotis Gouveris
    • 1
    • 2
  • Petros Kopteridis
    • 1
  • Dioynissis Loukeris
    • 1
  • Frantzeska Sigala
    • 3
  • Alexandra Zorbala-Sypsa
    • 4
  • Evangelos Felekouras
    • 3
  • Efstathios Papalambros
    • 3
  1. 1.Department of PathophysiologyOncology UnitGreece
  2. 2.Second Department of Medical Oncology“Metaxa” Memorial Cancer HospitalPiraeusGreece
  3. 3.First Surgical DepartmentGreece
  4. 4.Radiology Department, Laikon General HospitalAthens University School of MedicineAthensGreece

Personalised recommendations